Q3 2024 saw continued focus on SI-053 clinical trial preparations, improved operating results, and a SEK 5 million loan to secure short-term liquidity. SI-053 protocol was adapted to new EU regulations, with European clinical development set to begin after year-end.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.